Project Grant R01CA294649
Award Date 8/18/25
Completion Date 7/31/29
Dollars Obligated $2.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Missouri, USA
Similar Awards
- The federal Project Grant award of $2,820,337, awarded by the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) on August 6, 2025, supports research to develop new methods for directly measuring and interrupting metabolic pathways in glioblastoma brain cancers. The project, led by researchers at the University of Michigan, aims to: 1) create new techniques to directly measure metabolic activity in mouse models and glioblastoma patients, and 2) conduct a clinical trial to...
- This federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) provides $682,596 to The University of Texas Southwestern Medical Center to conduct research on the metabolic mechanisms driving glioma progression. The key research objectives are to: 1) Dissect the molecular basis for metabolic reprogramming and aberrant metabolite secretion in high-grade gliomas; 2) Determine the impact of aberrant metabolite secretion on the tumor microenvironment; and...
- This $732,000 Project Grant from the National Cancer Institute, part of the Department of Health and Human Services, will support research under the Cancer Treatment Research program. The grant recipient, Northwestern University, will develop a bridge-lipid nanoparticle platform to reprogram immunosuppressive tumor-associated myeloid cells and potentiate radiotherapy for glioblastoma. Over a five-year period, the university will conduct three aims: harnessing myeloid cells to phagocytose...
- The National Cancer Institute (NCI) awarded a $136,412 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to the Regents of the University of Michigan. The grant, entitled "Defining and Interrupting Metabolic Crosstalk in the Glioblastoma Microenvironment," will support research to investigate how glioblastoma brain tumors acquire and utilize specific metabolites from the brain environment to support tumor growth and therapeutic resistance. The project will run from...
- This federal Project Grant award of $659,325 from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853), supports research to investigate neuro-immune mechanisms in mutant IDH1 gliomas. The project, awarded to the Regents of the University of Michigan, focuses on molecular profiling of gliomas to better understand their pathophysiology. Key objectives include identifying...
- This federal Project Grant award of $429,000.00 was made on August 1, 2025 by the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program. The goal of this research is to explore the mechanism of Notch inhibition resistance in glioblastoma (GBM) cancer stem-like cells in order to develop novel therapies for this deadly disease. The research aims to identify GBM patient subsets...
- The National Cancer Institute (NCI), a component of the Department of Health and Human Services National Institutes of Health, awarded a $162,486 Project Grant under the Cancer Research Manpower (CFDA 93.398) federal grant program to Case Western Reserve University in Cleveland, OH. The grant supports research to study the regulation of translation (mRNA-to-protein) in glioblastoma stem-like cells as a mechanism of adaptation to the hypoxic tumor microenvironment. The research approach uses...
- This federal Project Grant award of $656,879 from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) supports research to investigate the mechanisms by which mutations in isocitrate dehydrogenase (IDH) genes drive the initiation of lower grade gliomas and their progression to high grade gliomas. The research is being conducted by The University of Texas Southwestern Medical...
- This federal Project Grant award for $432,134 was provided by the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395). The grant supports a research project titled "Targeted Radioimmunotherapy for Glioblastoma" conducted by the University of Texas MD Anderson Cancer Center. The project aims to develop a targeted radioimmunotherapy approach to treat glioblastoma, a highly aggressive form of brain cancer. The research will explore the use of...
- The U.S. National Cancer Institute (NCI) awarded a Project Grant under the Cancer Treatment Research program (CFDA 93.395) to The General Hospital Corporation, doing business as Massachusetts General Hospital (MGH), to conduct research focused on harnessing mutant IDH1 as a therapeutic target in liver cancer and other solid malignancies. The $693,781 grant, awarded on April 14, 2025, will support research to understand how IDH1 inhibitors slow cancer growth and why resistance ultimately...